The National Institute for Health and Care Excellence (NICE) is planning to evaluate the pharmaceutical firm Norgine's medical device Endocuff Vision for use in colonoscopy, through its medical technologies evaluation programme.

A Class I sterile medical device, Endocuff Vision is designed to identify pre-cancerous polyps in patients undergoing bowel cancer screening.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Proven to improve the detection of adenomas and polyps when compared to standard colonoscopy, the device can be attached to the end of the colonoscope, which enables better field of view by holding back colonic folds during colonoscope withdrawal.

"It is reported that the identification and elimination of pre-cancerous polyps during colonoscopy minimises the development of and death from colorectal cancer."

Norgine UK & ROI general manager Bob Cuffe said: “Norgine is confident that the use of Endocuff Vision brings value to healthcare systems and patients by increasing the detection of cancerous polyps in patients undergoing bowel cancer screening and surveillance.”

It is reported that the identification and elimination of pre-cancerous polyps during colonoscopy minimises the development of and death from colorectal cancer.

Part of Norgine’s colonoscopy portfolio including Klean-Prep and Moviprep, the device is available through Olympus Corporation of the Americas in the US and Canada.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is also available via the firm's infrastructure in Australia, Austria, Belgium, Finland, France, Denmark, Germany, Italy, Ireland, Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland and the UK.

With headquarters in the Netherlands and its global operations in Amsterdam and Harefield, UK, the firm owns a R&D site in Hengoed, Wales, UK and manufacturing sites in Hengoed and in Dreux, France.